EUROAPI was originally incubated, structured, and spun off by the major French pharmaceutical corporation Sanofi to independently manage active pharmaceutical ingredient manufacturing. While Sanofi initially retained a significant minority equity stake following the company's public listing on Euronext Paris to maintain a strategic long-term customer partnership, EUROAPI operates as an independent publicly traded enterprise.